Literature DB >> 11266079

Characterization of (+/-)-bufuralol hydroxylation activities in liver microsomes of Japanese and Caucasian subjects genotyped for CYP2D6.

T Shimada1, F Tsumura, H Yamazaki, F P Guengerich, K Inoue.   

Abstract

Twenty-four genetic polymorphisms in the CYP2D6 gene were analysed in liver DNA samples of 39 Japanese and 44 Caucasians and compared with CYP2D6 protein levels and bufuralol 1'- and 6-hydroxylation activities in liver microsomes of these human samples. We detected 13 types of CYP2D6 genetic polymorphisms and classified these into 20 genotypes; nine types were found in Japanese and 14 types in Caucasian samples. CYP2D6*10B, but not CYP2D6*10A, was the most frequent (34.6%) in Japanese. In Caucasians, several CYP2D6 polymorphisms including CYP2D6*4, *4D, *4E, *4L, *3, *9, *5 and *2E (frequencies of 6.8, 3.4, 4.5, 9.1, 1.1, 2.3, 2.3 and 4.5%, respectively) were detected. A Caucasian having CYP2D6*3/*5 had a protein with slower gel mobility (immunoblotting with anti-CYP2D6 antibody) and very low activity for bufuralol 1'-hydroxylation. Five Caucasian samples (CYP2D6*4/*4, *4/*4L, or *4D/*4L) had no measurable CYP2D6 protein and very low bufuralol 1'-hydroxylation activities. Seven Japanese subjects with CYP2D6*10B/*10B had CYP2D6 protein at levels of approximately 20% of those present in humans with CYP2D6*1 and *2 and catalysed bufuralol 1'-hydroxylation at low rates. Kinetic analysis of bufuralol 1'- and 6-hydroxylation indicates that (i) the Km values for 1'-hydroxylation were lower in individuals with CYP2D6*1/*1, *1/*2, *1/*2X2, and *2/*2 than those with CYP2D6*4/*4, *4/*4L, *4D/*4L, or *10B/*10B and Vmax values tended to be higher in the former groups (*1, *2), and (ii) individuals with heterozygous CYP2D6*1/*4D, *1/*4L, and *1/*5 had relatively high Vmax/Km ratios, whereas individuals with heterozygous CYP2D6*1/*9, *2/4D, *2/*5, *2/*10B, *2E/*4E, *3/*5, *4L/*9, and *10B/*39 had lower Vmax/Km ratios for bufuralol 1'-hydroxylation. Quinidine inhibited bufuralol 1'-hydroxylation in liver microsomes, particularly at low substrate concentrations, in individuals with CYP2D6*1/*1, and 1/1*2, but not those with CYP2D6*4/*4 and very slightly in individuals with CYP2D6*10B/*10B. The latter two groups were found to be more sensitive to alpha-naphthoflavone than the former groups, indicative of the contribution of CYP1A2. These results support the view that CYP2D6*3, *4, *4D, and *4L are major genotypes producing poor metabolizer phenotypes in CYP2D6 in Caucasians, whereas CYP2D6*10B is a major factor in decreased CYP2D6 protein expression and catalytic activities in Japanese.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11266079     DOI: 10.1097/00008571-200103000-00005

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  7 in total

1.  Metabolic capabilities of cytochrome P450 enzymes in Chinese liver microsomes compared with those in Caucasian liver microsomes.

Authors:  Junling Yang; Minxia M He; Wei Niu; Steven A Wrighton; Li Li; Yang Liu; Chuan Li
Journal:  Br J Clin Pharmacol       Date:  2012-02       Impact factor: 4.335

2.  Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans.

Authors:  A Gaedigk; A Bhathena; L Ndjountché; R E Pearce; S M Abdel-Rahman; S W Alander; L DiAnne Bradford; P K Rogan; J Steven Leeder
Journal:  Pharmacogenomics J       Date:  2005       Impact factor: 3.550

Review 3.  Quantitative Proteomics in Translational Absorption, Distribution, Metabolism, and Excretion and Precision Medicine.

Authors:  Deepak Ahire; Laken Kruger; Sheena Sharma; Vijaya Saradhi Mettu; Abdul Basit; Bhagwat Prasad
Journal:  Pharmacol Rev       Date:  2022-07       Impact factor: 18.923

4.  An in vitro interethnic comparison of monoamine oxidase activities between Japanese and Caucasian livers using rizatriptan, a serotonin receptor 1B/1D agonist, as a model drug.

Authors:  T Iwasa; H Sano; A Sugiura; N Uchiyama; K Hara; H Okochi; K Nakagawa; T Yasumori; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  2003-11       Impact factor: 4.335

5.  CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with reduced CYP3A4 protein level and function in human liver microsomes.

Authors:  Maho Okubo; Norie Murayama; Makiko Shimizu; Tsutomu Shimada; F Peter Guengerich; Hiroshi Yamazaki
Journal:  J Toxicol Sci       Date:  2013       Impact factor: 2.196

6.  Methodology for clinical genotyping of CYP2D6 and CYP2C19.

Authors:  Beatriz Carvalho Henriques; Avery Buchner; Xiuying Hu; Yabing Wang; Vasyl Yavorskyy; Keanna Wallace; Rachael Dong; Kristina Martens; Michael S Carr; Bahareh Behroozi Asl; Joshua Hague; Sudhakar Sivapalan; Wolfgang Maier; Mojca Z Dernovsek; Neven Henigsberg; Joanna Hauser; Daniel Souery; Annamaria Cattaneo; Ole Mors; Marcella Rietschel; Gerald Pfeffer; Stacey Hume; Katherine J Aitchison
Journal:  Transl Psychiatry       Date:  2021-11-22       Impact factor: 6.222

7.  Prediction of the CYP2D6 enzymatic activity based on investigating of the CYP2D6 genotypes around the vivax malaria patients in Yunnan Province, China.

Authors:  Ying Dong; Herong Huang; Yan Deng; Yanchun Xu; Mengni Chen; Yan Liu; Canglin Zhang
Journal:  Malar J       Date:  2021-11-25       Impact factor: 2.979

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.